Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer’s Disease and Multiple Sclerosis

Ainhoa Etxeberría(University of California, San Francisco), Christopher J. Bohlen(Neurological Surgery), Alicia Nugent(Gene Therapy Laboratory), Meena Choi(Translational Genomics Research Institute), Sean M. Silverman(National Institutes of Health), Justin Elstrott, Weng Ruh Wong(Microsemi (Canada)), Hai Ngu, Guita Lalehzadeh(Sunesis (United States)), Mitchell G. Rezzonico(Bioinformatics Institute), Isidro Hötzel(San Francisco Public Library), Robby M. Weimer(Sunesis (United States)), Monica Xiong(Hope Center for Neurological Disorders), Alvin Gogineni(Angiogenesis Foundation), Ben Chih(Gene Therapy Laboratory), Gillie A. Roth(Stanford University), Chang Hoon Cho(Gene Therapy Laboratory), Max Adrian, William J. Meilandt, Gloriia Novikova(Icahn School of Medicine at Mount Sinai), Yi-Chun Hsiao, Shraddha Sadekar(American Pharmacists Association), Tracy J. Yuen(Tetra Therapeutics (United States)), Oded Foreman, Brad A. Friedman(Gene Therapy Laboratory), Jacob J. Greene(Sunesis (United States)), Allison Soung(Washington University in St. Louis), Amy Easton, Luke Xie(Sunesis (United States)), Rebecca Leahey(Sunesis (United States)), Martin Weber, Soumitra Ghosh(Neuroscience Institute), Qingling Li(Microsemi (Canada)), Kimberly L. Stark(Neuroscience Institute), Pamela Chan, Changchun Du, Yun‐An Shen(Sunesis (United States)), Stephen Vito(Sunesis (United States)), Wendy Sandoval(Abterra Biosciences (United States)), Man Kin Choy(Sunesis (United States)), Jose Imperio(Sunesis (United States))
Journal of Neuroscience
June 3, 2024
Cited by 28


Related Papers